El rituximab en el linfoma

Categoría Resumen estructurado de revisiones sistemáticas
RevistaDatabase of Abstracts of Reviews of Effects (DARE)
Año 2005
Cargando información sobre las referencias

CRD SUMMARY:

This well-conducted review found that rituximab is generally well tolerated and may improve response in people with low-grade lymphoma. There were insufficient data on long-term outcomes or people with histological subtypes other than low-grade lymphoma. CHOP chemotherapy plus rituximab appears to improve response and survival more than CHOP alone in people with diffuse large B cell lymphoma.
Epistemonikos ID: eb9b8ed594acaf722bc90a981636789a312d1565
First added on: Jun 08, 2012